What is Sihuan Pharmaceutical Holdings Group EBITDA Margin %?
Sihuan Pharmaceutical Holdings GroupSHPHF 52 EBITDA Margin % is 32.10% as of Dec. 2025, which is 3% above its 10-year median of 31.31. GuruFocus rates SHPHF with a GF Score™ of 52/100 and a GF Value™ of $0.17 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Sihuan Pharmaceutical Holdings Group ranks better than 89.01% on this metric.
Sihuan Pharmaceutical Holdings Group (OTCPK:SHPHF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sihuan Pharmaceutical Holdings Group EBITDA Margin % Related Terms
Sihuan Pharmaceutical Holdings Group EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sihuan Pharmaceutical Holdings Group EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group (SHPHF) has a EBITDA Margin % of 32.10% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. This is near median its historical median of 31.31. According to the industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #105 out of 955 companies in the Drug Manufacturers industry, placing it in the top 11%.
Is Sihuan Pharmaceutical Holdings Group's EBITDA Margin % too high?
Sihuan Pharmaceutical Holdings Group's current EBITDA Margin % of 32.10% is near median its 10-year median of 31.31. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Sihuan Pharmaceutical Holdings Group's value of 32.10% is 159.1% above this industry median. Based on the distribution chart, Sihuan Pharmaceutical Holdings Group ranks #105 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #105 out of 955 companies for EBITDA Margin %. This places Sihuan Pharmaceutical Holdings Group in the top 11% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Sihuan Pharmaceutical Holdings Group's value of 32.10% is 159.1% above this benchmark. While the company's 10-year median is 31.31 vs. the industry median of 12.39, Sihuan Pharmaceutical Holdings Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sihuan Pharmaceutical Holdings Group's current EBITDA Margin % of 32.10% is 159.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sihuan Pharmaceutical Holdings Group and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sihuan Pharmaceutical Holdings Group's current EBITDA Margin % is 32.10%, which is near median its own 10-year median of 31.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (SHPHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.17, compared to a current price of $0.13 — trading 23.7% below its estimated fair value. The current EBITDA Margin % is 32.10%, which is near median its 10-year median of 31.31 and 159.1% above the Drug Manufacturers industry median of 12.39. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (SHPHF), the current EBITDA Margin % is 32.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sihuan Pharmaceutical Holdings Group (SHPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued.
The current stock price of $0.13 is trading 23.7% below its estimated GF Value™ of $0.17.
GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.
Key valuation signals for SHPHF:
EBITDA Margin %: 32.10% (near median its 10-year median of 31.31)
GF Value™: $0.17 vs. price of $0.13 (23.7% below fair value)
Industry Position: 159.1% above the Drug Manufacturers median (#105 of 955)
No single metric tells the full story. See the SHPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sihuan Pharmaceutical Holdings Group Business Description
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
52GF Score
Get the complete analysis for SHPHF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPHF has been successfully added to your 
